Alamar Biosciences, Inc. - Class A common stock (ALMR)

Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings call since completing its April initial public offering. Chief

The aggressive growth fund investor was busy adding to some of her established stakes on Monday.